Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions
Illumina (NASDAQ: ILMN) has announced a strategic collaboration with Broad Clinical Labs to scale single-cell research projects using advanced tools and workflows. The partnership aims to create a 5 billion cell atlas within three years, leveraging Illumina's Single Cell Prep, NovaSeq™ X Plus platform, 25B flow cell, and DRAGEN™ analysis software.
The collaboration combines Illumina's sequencing expertise with Broad's experience in translating complex molecular biology assays into high-throughput workflows. The partnership will utilize cutting-edge techniques like Perturb-seq and CRISPR screens to process and analyze large volumes of single-cell reads, accelerating discoveries in disease modeling and drug development.
This end-to-end workflow solution aims to enable high-throughput processing of single-cell samples with enhanced speed and accuracy, supporting the development of large-scale functional genomics studies.
Illumina (NASDAQ: ILMN) ha annunciato una collaborazione strategica con Broad Clinical Labs per ampliare i progetti di ricerca su singole cellule utilizzando strumenti e flussi di lavoro avanzati. L'obiettivo della partnership è creare un atlante di 5 miliardi di cellule entro tre anni, sfruttando il Single Cell Prep di Illumina, la piattaforma NovaSeq™ X Plus, il flusso di celle da 25B e il software di analisi DRAGEN™.
La collaborazione unisce l'expertise di sequenziamento di Illumina con l'esperienza di Broad nella traduzione di complessi saggi di biologia molecolare in flussi di lavoro ad alta capacità. La partnership utilizzerà tecniche all'avanguardia come Perturb-seq e schermi CRISPR per elaborare e analizzare grandi volumi di letture di singole cellule, accelerando le scoperte nella modellazione delle malattie e nello sviluppo di farmaci.
Questa soluzione di flusso di lavoro end-to-end mira a consentire l'elaborazione ad alta capacità di campioni di singole cellule con maggiore velocità e precisione, supportando lo sviluppo di studi di genomica funzionale su larga scala.
Illumina (NASDAQ: ILMN) ha anunciado una colaboración estratégica con Broad Clinical Labs para escalar proyectos de investigación de células individuales utilizando herramientas y flujos de trabajo avanzados. La asociación tiene como objetivo crear un atlas de 5 mil millones de células en tres años, aprovechando el Single Cell Prep de Illumina, la plataforma NovaSeq™ X Plus, la celda de flujo de 25B y el software de análisis DRAGEN™.
La colaboración combina la experiencia en secuenciación de Illumina con la experiencia de Broad en la traducción de ensayos complejos de biología molecular en flujos de trabajo de alto rendimiento. La asociación utilizará técnicas de vanguardia como Perturb-seq y pantallas CRISPR para procesar y analizar grandes volúmenes de lecturas de células individuales, acelerando los descubrimientos en modelado de enfermedades y desarrollo de fármacos.
Esta solución de flujo de trabajo de extremo a extremo tiene como objetivo permitir el procesamiento de alto rendimiento de muestras de células individuales con mayor velocidad y precisión, apoyando el desarrollo de estudios de genómica funcional a gran escala.
Illumina (NASDAQ: ILMN)는 Broad Clinical Labs와 협력하여 고급 도구와 작업 흐름을 사용하여 단일 세포 연구 프로젝트를 확장한다고 발표했습니다. 이 파트너십의 목표는 Illumina의 Single Cell Prep, NovaSeq™ X Plus 플랫폼, 25B 흐름 셀 및 DRAGEN™ 분석 소프트웨어를 활용하여 3년 이내에 50억 세포 아틀라스를 만드는 것입니다.
이 협력은 Illumina의 시퀀싱 전문성과 Broad의 복잡한 분자 생물학 분석을 고처리량 작업 흐름으로 변환하는 경험을 결합합니다. 이 파트너십은 Perturb-seq 및 CRISPR 스크린과 같은 최첨단 기술을 활용하여 단일 세포 판독의 대량 처리를 가속화하고, 질병 모델링 및 약물 개발에서의 발견을 촉진합니다.
이 종합 워크플로우 솔루션은 단일 세포 샘플의 고처리량 처리를 보다 빠르고 정확하게 수행할 수 있도록 하여 대규모 기능 유전체 연구의 개발을 지원하는 것을 목표로 합니다.
Illumina (NASDAQ: ILMN) a annoncé une collaboration stratégique avec Broad Clinical Labs pour étendre les projets de recherche sur les cellules uniques en utilisant des outils et des flux de travail avancés. L'objectif de ce partenariat est de créer un atlas de 5 milliards de cellules dans les trois prochaines années, en s'appuyant sur le Single Cell Prep d'Illumina, la plateforme NovaSeq™ X Plus, la cellule de flux de 25B et le logiciel d'analyse DRAGEN™.
Cette collaboration combine l'expertise en séquençage d'Illumina avec l'expérience de Broad dans la traduction d'essais complexes de biologie moléculaire en flux de travail à haut débit. Le partenariat utilisera des techniques de pointe telles que Perturb-seq et les écrans CRISPR pour traiter et analyser de grands volumes de lectures de cellules uniques, accélérant ainsi les découvertes dans la modélisation des maladies et le développement de médicaments.
Cette solution de flux de travail de bout en bout vise à permettre le traitement à haut débit des échantillons de cellules uniques avec une vitesse et une précision accrues, soutenant le développement d'études de génomique fonctionnelle à grande échelle.
Illumina (NASDAQ: ILMN) hat eine strategische Zusammenarbeit mit Broad Clinical Labs angekündigt, um Forschungsprojekte auf Einzelzellebene mit fortschrittlichen Werkzeugen und Arbeitsabläufen zu skalieren. Ziel der Partnerschaft ist es, innerhalb von drei Jahren ein Atlas von 5 Milliarden Zellen zu erstellen, wobei die Single Cell Prep von Illumina, die NovaSeq™ X Plus-Plattform, die 25B-Flusszelle und die DRAGEN™-Analysetools genutzt werden.
Die Zusammenarbeit kombiniert Illuminas Sequenzierungsexpertise mit Broads Erfahrung in der Übersetzung komplexer molekularbiologischer Tests in hochgradige Arbeitsabläufe. Die Partnerschaft wird modernste Techniken wie Perturb-seq und CRISPR-Screens nutzen, um große Mengen an Einzelzell-Lesungen zu verarbeiten und zu analysieren, was Entdeckungen in der Krankheitsmodellierung und der Arzneimittelentwicklung beschleunigt.
Diese End-to-End-Workflow-Lösung zielt darauf ab, die Hochdurchsatzverarbeitung von Einzelzellproben mit verbesserter Geschwindigkeit und Genauigkeit zu ermöglichen und die Entwicklung von großangelegten funktionellen Genomikstudien zu unterstützen.
- Partnership enables creation of 5 billion cell atlas within 3 years
- Integration of cutting-edge technologies (Perturb-seq, CRISPR screens) with Illumina's established platforms
- Development of high-throughput end-to-end workflow solution
- Reliance on third-party suppliers for critical components
- Uncertainty in customer acceptance of new products
- Manufacturing challenges in scaling operations
Insights
This strategic collaboration marks a pivotal moment in the $5.3 billion single-cell analysis market, positioning Illumina to capture a larger share of this rapidly growing segment. The partnership leverages Illumina's NovaSeq X Plus platform and DRAGEN software with Broad's expertise in high-throughput workflows, creating a formidable competitive advantage in the single-cell sequencing space.
The ambitious goal of creating a 5 billion cell atlas within three years is particularly significant for three reasons: First, it represents an unprecedented scale that could revolutionize our understanding of cellular biology and disease mechanisms. Second, it will likely drive substantial recurring revenue through increased consumables usage across Illumina's installed base. Third, it strengthens Illumina's position in the pharmaceutical research market, where single-cell analysis is becoming important for drug discovery and development.
The integration of CRISPRPerturb-seq with Illumina's workflow solutions addresses a critical bottleneck in drug discovery - the ability to rapidly screen and analyze genetic perturbations at scale. This could potentially reduce early-stage drug development timelines by 30-40% through more efficient target identification and validation.
The partnership's focus on standardization and scalability is particularly strategic, as it addresses the current market challenge of reproducibility in single-cell studies. By establishing standardized workflows, Illumina is effectively creating a new industry benchmark that could lead to increased adoption of their platforms in both academic and pharmaceutical research settings.
Longstanding partners bring together end-to-end workflows and leading CRISPR
Perturb-seq technologies setting a standard for single-cell studies and enabling a 5
billion single-cell atlas ecosystem within three years
Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years.
"Disease doesn't wait, and neither do we – Broad Clinical Labs and Illumina are unlocking the massive opportunities of single-cell sequencing to build a deeper understanding of biology," said Steve Barnard, Chief Technology Officer at Illumina. "Illumina has set the standard in whole genome sequencing, and now, with Broad's deep experience and long history of translating complex molecular biology assays into high-throughput, high quality workflows, we're doing the same with single-cell technology to advance precision health."
"Supporting the entire -omics ecosystem in building these capabilities enables significantly greater insights into key drivers of disease and more rapid translation of these insights into better precision care," said Niall Lennon, Chairman of the Board and Chief Scientific Officer at Broad Clinical Labs.
"By expanding our partnership to single-cell solutions, we're making significant strides to understand the roots of disease and close the gap between new biological insights and impact for patients," said Aziz Al'Khafaji, Director of Molecular R&D at Broad Clinical Labs. "The capabilities we're building, like combining Perturb-seq with Illumina Single Cell 3' RNA Prep, will support rapid and consistent data generation like we've demonstrated in the whole genome space, giving the research community the ability to create billion-cell atlas studies to make the next discoveries."
The combination of Illumina's Single Cell Prep, NovaSeq™ X Plus platform, 25B flow cell and DRAGEN™ analysis software creates a seamless end-to-end workflow enabling the high-throughput processing of single-cell samples.
Broad Clinical Labs will use this leading workflow alongside state-of-the-art techniques like Perturb-seq, CRISPR screens, and other cutting-edge applications. Together, these capabilities will help researchers process and analyze unprecedented volumes of single-cell reads with unparalleled speed and accuracy to make large-scale functional genomics studies possible and accelerate discovery in areas such as disease modeling and drug development.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables; and (iii) the acceptance by customers of our newly launched products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Broad Clinical Labs
Broad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis, and treatment of disease by pursuing projects, developing products, and driving adoption of cutting edge -omics technologies and novel molecular assays. Broad Clinical Labs is a leader in translational genomics, having sequenced over 700,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. www.broadclinicallabs.org
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-broad-clinical-labs-usher-in-new-era-of-drug-discovery-with-collaboration-to-rapidly-scale-single-cell-solutions-302382129.html
SOURCE Illumina, Inc.
FAQ
What is the goal of Illumina's collaboration with Broad Clinical Labs for single-cell research?
What technologies will ILMN use in this single-cell research partnership?
How will the Illumina-Broad Clinical Labs partnership advance drug discovery?
What are the main risks associated with ILMN's single-cell research initiative?
